Biogen Idec Announces Top-Line Results From Phase II Clinical Trial Of Baminercept In Rheumatoid Arthritis
Biogen Idec (NASDAQ: BIIB) announced today that its Phase II trial of baminercept (BG9924, LTBR-Ig) in rheumatoid arthritis (RA) patients who have had an inadequate response to conventional therapy with a disease-modifying antirheumatic drug (DMARD) did not meet its primary endpoint. The primary endpoint was defined as the proportion of baminercept-treated patients who achieved an ACR50 response, a standard measure of disease improvement in RA, compared to placebo at 14 weeks.
More: continued here
Filed under: Bones on October 13th, 2008